New FTC com­mis­sion­er could turn the tide for an in­ves­ti­ga­tion in­to PBMs

The Sen­ate last week vot­ed along par­ty lines, 51-50, with Vice Pres­i­dent Ka­mala Har­ris cast­ing the tie-break­er, to make Pres­i­dent Biden ap­pointee Al­varo Bedoya the de­cid­ing vote on a split 2-2 Fed­er­al Trade Com­mis­sion.

The ad­di­tion of Bedoya to the FTC could not on­ly spell more trou­ble for bio­phar­ma M&A ac­tiv­i­ty, as he may align with his De­mo­c­rat part­ners to break the FTC ties, but it may al­so mean that FTC Chair Lina Khan has what she needs to move for­ward on a study around the phar­ma mid­dle­men known as phar­ma­cy ben­e­fit man­agers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER